- Home
- ZJYL vs ADVM Comparison
ZJYL vs ADVM Comparison
Compare ZJYL & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZJYL
- ADVM
- Stock Information
- Founded
- ZJYL 2006
- ADVM 2006
- Country
- ZJYL China
- ADVM United States
- Employees
- ZJYL N/A
- ADVM N/A
- Industry
- ZJYL Industrial Specialties
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZJYL Consumer Discretionary
- ADVM Health Care
- Exchange
- ZJYL Nasdaq
- ADVM Nasdaq
- Market Cap
- ZJYL 127.4M
- ADVM 119.6M
- IPO Year
- ZJYL 2023
- ADVM 2014
- Fundamental
- Price
- ZJYL $0.76
- ADVM $3.94
- Analyst Decision
- ZJYL
- ADVM Strong Buy
- Analyst Count
- ZJYL 0
- ADVM 6
- Target Price
- ZJYL N/A
- ADVM $27.83
- AVG Volume (30 Days)
- ZJYL 256.9K
- ADVM 149.4K
- Earning Date
- ZJYL 01-01-0001
- ADVM 03-17-2025
- Dividend Yield
- ZJYL N/A
- ADVM N/A
- EPS Growth
- ZJYL 18.46
- ADVM N/A
- EPS
- ZJYL 0.02
- ADVM N/A
- Revenue
- ZJYL $23,502,010.00
- ADVM $1,000,000.00
- Revenue This Year
- ZJYL N/A
- ADVM N/A
- Revenue Next Year
- ZJYL N/A
- ADVM $1,342.84
- P/E Ratio
- ZJYL $32.52
- ADVM N/A
- Revenue Growth
- ZJYL 18.57
- ADVM N/A
- 52 Week Low
- ZJYL $0.70
- ADVM $3.85
- 52 Week High
- ZJYL $11.15
- ADVM $22.30
- Technical
- Relative Strength Index (RSI)
- ZJYL 43.01
- ADVM 38.74
- Support Level
- ZJYL $0.77
- ADVM $3.85
- Resistance Level
- ZJYL $0.90
- ADVM $4.63
- Average True Range (ATR)
- ZJYL 0.09
- ADVM 0.30
- MACD
- ZJYL -0.01
- ADVM -0.01
- Stochastic Oscillator
- ZJYL 1.50
- ADVM 8.76
About ZJYL JIN MEDICAL INTERNATIONAL LTD.
Jin Medical International Ltd offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other living aids products to be used by people with disabilities or impaired mobility. The company's products are sold to distributors in both China and overseas markets. Its product offerings comprise Wheelechaire serirs, Bath products, oxygen machines, and nursing products. Geographically, it generates the majority of its revenue from Japan.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.